Home >> Research Area >>Neuroscience>>5-HT Receptor>> (S)-WAY 100135 dihydrochloride

(S)-WAY 100135 dihydrochloride

5-HT1A receptor antagonist,potent and selective CAS# 149007-54-5

(S)-WAY 100135 dihydrochloride

Catalog No. BCC6993----Order now to get a substantial discount!

Product Name & Size Price Stock
(S)-WAY 100135 dihydrochloride: 5mg $92 In Stock
(S)-WAY 100135 dihydrochloride: 10mg Please Inquire In Stock
(S)-WAY 100135 dihydrochloride: 20mg Please Inquire Please Inquire
(S)-WAY 100135 dihydrochloride: 50mg Please Inquire Please Inquire
(S)-WAY 100135 dihydrochloride: 100mg Please Inquire Please Inquire
(S)-WAY 100135 dihydrochloride: 200mg Please Inquire Please Inquire
(S)-WAY 100135 dihydrochloride: 500mg Please Inquire Please Inquire
(S)-WAY 100135 dihydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (S)-WAY 100135 dihydrochloride

Number of papers citing our products

Chemical structure

(S)-WAY 100135 dihydrochloride

3D structure

Chemical Properties of (S)-WAY 100135 dihydrochloride

Cas No. 149007-54-5 SDF Download SDF
PubChem ID 14801905 Appearance Powder
Formula C24H35Cl2N3O2 M.Wt 468.47
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 5 mM in water with gentle warming and to 10 mM in water with sonication
Chemical Name N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide;dihydrochloride
SMILES CC(C)(C)NC(=O)C(CN1CCN(CC1)C2=CC=CC=C2OC)C3=CC=CC=C3.Cl.Cl
Standard InChIKey VJGZNBYDSDEOED-UHFFFAOYSA-N
Standard InChI InChI=1S/C24H33N3O2.2ClH/c1-24(2,3)25-23(28)20(19-10-6-5-7-11-19)18-26-14-16-27(17-15-26)21-12-8-9-13-22(21)29-4;;/h5-13,20H,14-18H2,1-4H3,(H,25,28);2*1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (S)-WAY 100135 dihydrochloride

DescriptionPotent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). Selective over 5-HT1B, 1C, 2,α1, α2 and D2 receptors (IC50 > 1000 nM). Centrally active on systemic administration.

(S)-WAY 100135 dihydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(S)-WAY 100135 dihydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (S)-WAY 100135 dihydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1346 mL 10.673 mL 21.3461 mL 42.6922 mL 53.3652 mL
5 mM 0.4269 mL 2.1346 mL 4.2692 mL 8.5384 mL 10.673 mL
10 mM 0.2135 mL 1.0673 mL 2.1346 mL 4.2692 mL 5.3365 mL
50 mM 0.0427 mL 0.2135 mL 0.4269 mL 0.8538 mL 1.0673 mL
100 mM 0.0213 mL 0.1067 mL 0.2135 mL 0.4269 mL 0.5337 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on (S)-WAY 100135 dihydrochloride

(S)-WAY 100135 dihydrochloride is a potent and selective antagonist of 5-HT1A receptor with IC50 value of 15 nM.

The 5-HT1A receptor is a G protein-coupled receptor for endogenous neurotransmitter serotonin (5-HT) and mediates inhibitory neurotransmission.

(S)-WAY 100135 dihydrochloride is a potent and selective somatodendritic and postsynaptic 5-HT1A receptors antagonist. (+/-)-WAY100135 inhibited 5-HT1A receptor in the rat hippocampal with IC50 value of 34 nM [1].

In the murine elevated plus-maze test, (S)-WAY 100135 (10 mg/kg) exhibited anxiolytic-like effects [2]. In free feeding rats, WAY-100135 (3 mg/kg) significantly inhibited hyperphagia and the increased incidence of feeding induced by 8-OH-DPAT (0.1 mg/kg), which was mediated by somatodendritic 5-HT1A autoreceptor [3]. In rats, (S)-WAY 100135 (0.2, 1, 5 ug/ul) inhibited the impairment of choice accuracy induced by intrahippocampal scopolamine (3.75 ug/ul) in a dose-dependent way. However, (S)-WAY 100135 didn’t influence the acquisition of spatial learning [4]. In rats, WAY-100135 (10.0 mg/kg) inhibited the decrease of 5-HT release induced by buspirone, a 5-HT1A receptor partial agonist [5].

References:
[1].  Fletcher A, Bill DJ, Bill SJ, et al. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmacol, 1993, 237(2-3): 283-291.
[2].  Rodgers RJ, Cole JC. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol, 1994, 261(3): 321-325.
[3].  Hartley JE, Fletcher A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur J Pharmacol, 1994, 252(3): 329-332.
[4].  Carli M, Luschi R, Samanin R. (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol, 1995, 283(1-3): 133-139.
[5].  Routledge C, Gurling J, Ashworth-Preece MA, et al. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol, 1995, 276(3): 281-284.

Featured Products
New Products
 

References on (S)-WAY 100135 dihydrochloride

Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test.[Pubmed:7813555]

Eur J Pharmacol. 1994 Aug 22;261(3):321-5.

The effects of (S)-WAY 100135 ((S)-N-tert-butyl-3-(4-(2-methoxyphenyl)- piperazin-1-yl)-2-phenyl-propanamide dihydrochloride; 2.5-20.0 mg/kg), a 5-HT1A receptor antagonist, on the behaviour of male mice were examined in the elevated plus-maze test of anxiety. An ethological scoring technique was used to provide a comprehensive profile of drug action. Only minor changes in behaviour were observed at 2.5 and 5.0 mg/kg, and consisted of reductions in some (though not all) risk assessment measures. At 10 mg/kg, the compound increased percent open arm entries and percent open arm time, without altering general activity levels. This classic anxiolytic-like profile was confirmed by major reductions in risk assessment measures including protected head-dips and protected stretched attend postures. Although many of the same changes were also observed at 20 mg/kg, the absence of an effect on percent open arm time and a tendency towards increased non-exploratory behaviour suggested (1) some loss of anxiolytic activity and (2) a possible contribution of non-specific factors at higher doses. Present findings indicate that (S)-WAY 100135 produces clear anxiolytic-like effects in the murine elevated plus-maze, a profile that can be distinguished from that produced by 5-HT1A receptor partial agonists in the same test.

WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.[Pubmed:8365456]

Eur J Pharmacol. 1993 Jun 24;237(2-3):283-91.

The novel phenylpiperazine derivative, (+/-)-WAY100135 (N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpro pionamide dihydrochloride), is a selective antagonist at both somatodendritic and postsynaptic 5-HT1A receptors. The IC50 of (+/-)-WAY100135 at the rat hippocampal 5-HT1A receptor was 34 nM, whereas its IC50 at a range of other receptor sites was > 2 microM. Up to a dose of 2.5 mg/kg i.v. (+/-)-WAY100135 induced a maximum 30% inhibition of raphe neuronal firing and (at 0.5 mg/kg i.v.) antagonised the inhibition of firing induced by 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) in anaesthetised rats. (+/-)-WAY100135 antagonised the action of 5-carboxamidoiodotryptamine in the guinea-pig ileum, with a pA2 of 7.2. (+/-)-WAY100135 had no agonist-like behavioural effects but antagonised the behavioural syndrome and hypothermia induced by 8-OH-DPAT in the rat and mouse, respectively. The interaction of (+/-)-WAY100135 with the 5-HT1A receptor was stereoselective; the (+)-enantiomer being markedly more active in binding, functional and behavioural studies. These data indicate that (+/-)-WAY100135 is the first highly selective antagonist at both somatodendritic and postsynaptic 5-HT1A receptors.

Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents.[Pubmed:8122313]

Trends Pharmacol Sci. 1993 Dec;14(12):41-8.

The 5-hydroxytryptamine 5-HT1A receptor has been the focus of considerable research effort for over a decade. However, the definitive classification of this receptor and the full characterization of its pharmacology have awaited the development of highly selective 5-HT1A receptor antagonists. The only compounds available until recently have been either nonselective or partial 5-HT1A receptor agonists (or a combination of both). Confusion has arisen owing to the use of different pharmacological models in examining the functional activity of 5-HT1A receptor ligands. Several partial agonists display only antagonist activity in models of postsynaptic 5-HT1A receptor function, whereas their agonist properties are revealed in models of presynaptic, somatodendritic 5-HT1A autoreceptor function. In view of these considerations, the term 'silent antagonist' has been introduced to distinguish true 5-HT1A receptor antagonists from partial agonists. Allan Fletcher and colleagues review the pharmacological properties of the first selective silent 5-HT1A receptor antagonists that have been recently discovered and discuss the potential therapeutic utility of these novel compounds.

Description

Potent, selective 5-HT1A antagonist

Keywords:

(S)-WAY 100135 dihydrochloride,149007-54-5,Natural Products,5-HT Receptor, buy (S)-WAY 100135 dihydrochloride , (S)-WAY 100135 dihydrochloride supplier , purchase (S)-WAY 100135 dihydrochloride , (S)-WAY 100135 dihydrochloride cost , (S)-WAY 100135 dihydrochloride manufacturer , order (S)-WAY 100135 dihydrochloride , high purity (S)-WAY 100135 dihydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: